EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY 4.0

Landmark clinical trials shaping contemporary guideline-directed medical therapy for heart failure

Michał Tkaczyszyn iD, Agnieszka Kapłon-Cieślicka, Maciej Janiszewski, Dominika Klimczak-Tomaniak, Ewa Jędrzejczyk-Patej, Paweł Burchardt, Amr Abdin, Michael Böhm iD, Ovidiu Chioncel iD, Guillaume Baudry iD, Marta Cobo Marcos, Robert Zymliński und 3 weitere

ESC Heart Failure · 04.07.2026 · 13 (4)

DOI: 10.1093/eschf/xvag141 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ESC Heart Failure, online erschienen am 22.05.2026. Verfasst von Michał Tkaczyszyn und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Clinical Department of Intensive Cardiac Care, Faculty of Medicine, Institute of Heart Diseases, Wroclaw Medical University…. Hauptthemen laut MEDLINE: Heart Failure, Practice Guidelines as Topic, Stroke Volume, Randomized Controlled Trials as Topic. Die Arbeit nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wroclaw Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) management has evolved substantially over recent decades, transitioning from predominantly symptomatic treatment to a strategy grounded in disease-modifying therapies that improve survival and reduce hospitalizations. This review provides a structured and clinically oriented synthesis of landmark randomized controlled trials (RCTs) that have shaped contemporary guideline-directed medical therapy across the spectrum of left ventricular ejection fraction (LVEF). Evidence from pivotal large-scale RCTs is presented according to pharmacological classes, encompassing both foundational and selected adjunctive therapies. In HF with reduced LVEF, multiple drug classes consistently reduce mortality and HF hospitalizations, forming the basis of contemporary quadruple therapy. In contrast, evidence in HF with mildly reduced or preserved LVEF remains more heterogeneous, with sodium–glucose co-transporter-2 inhibitors emerging as the only class with consistent benefit across the full LVEF spectrum. Additional therapies, including digoxin, vericiguat, intravenous iron, and emerging incretin-based agents, provide incremental benefits in selected clinical contexts. Differences in trial populations, design, and background therapy limit direct comparisons but highlight the progressive refinement of HF treatment strategies. Despite the strength of the evidence base, a persistent gap remains between guideline recommendations and real-world implementation. Bridging this gap, improving representation of under-represented populations in clinical trials, and advancing precision medicine approaches remain key priorities for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailurePractice Guidelines as TopicStroke VolumeRandomized Controlled Trials as TopicVentricular Function, LeftHumans

Stichwörter der Autor:innen

Guideline-directed medical therapyHeart failurePharmacotherapy

Autor:innen und Institutionen

  • Department of Cardiology, Clinical Department of Intensive Cardiac Care, Faculty of Medicine, Institute of Heart Diseases, Wroclaw Medical University, Borowska 213, Wroclaw 50-556, Poland.
  • Department of Cardiology, Jan Mikulicz Radecki University Hospital in Wrocław, Borowska 213, Wroclaw 50-556, Poland.
  • First Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
  • Department of Heart Failure and Cardiac Rehabilitation, Medical University of Warsaw, Kondratowicza 8, Warsaw 03-242, Poland.
  • Department of Cardiology, Hypertension and Internal Medicine, Mazovian Bródno Hospital, Kondratowicza 8, Warsaw 03-242, Poland.
  • First Department of Cardiology and Angiology, Silesian Centre for Heart Diseases, Zabrze, Poland.

ORCID-Profile: Michał Tkaczyszyn, Michael Böhm, Ovidiu Chioncel, Guillaume Baudry

Förderung

  • Wroclaw Medical University

Zitieren

APA

Tkaczyszyn, M., Kapłon-Cieślicka, A., Janiszewski, M., Klimczak-Tomaniak, D., Jędrzejczyk-Patej, E., Burchardt, P., Abdin, A., Böhm, M., Chioncel, O., Baudry, G., Cobo Marcos, M., Zymliński, R., Núñez, J., Metra, M., & Ponikowski, P. (2026). Landmark clinical trials shaping contemporary guideline-directed medical therapy for heart failure. ESC Heart Failure, 13(4). https://doi.org/10.1093/eschf/xvag141

Vancouver

Tkaczyszyn M, Kapłon-Cieślicka A, Janiszewski M, Klimczak-Tomaniak D, Jędrzejczyk-Patej E, Burchardt P, et al. Landmark clinical trials shaping contemporary guideline-directed medical therapy for heart failure. ESC Heart Failure. 2026;13(4). doi:10.1093/eschf/xvag141

BibTeX
@article{Tkaczyszyn2026,
  author = {Tkaczyszyn, Michał and Kapłon-Cieślicka, Agnieszka and Janiszewski, Maciej and Klimczak-Tomaniak, Dominika and Jędrzejczyk-Patej, Ewa and Burchardt, Paweł and Abdin, Amr and Böhm, Michael and Chioncel, Ovidiu and Baudry, Guillaume and Cobo Marcos, Marta and Zymliński, Robert and Núñez, Julio and Metra, Marco and Ponikowski, Piotr},
  title = {Landmark clinical trials shaping contemporary guideline-directed medical therapy for heart failure},
  journal = {ESC Heart Failure},
  year = {2026},
  volume = {13},
  number = {4},
  doi = {10.1093/eschf/xvag141}
}
Kostenlos starten →